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ABSTRACT The presence of the P2Y2 (P2U-purinergic)
receptor on the apical surface of airway tissue raises the
possibility that aerosolized UTPmight be used therapeutically
to induce Cl2 secretion in individuals with cystic fibrosis.
However, the duration of the effects of UTP may be limited by
enzymatic degradation. We therefore have analyzed the me-
tabolism of UTP and its metabolite UDP on polarized human
nasal epithelium (HNE), and have compared the pharmaco-
logical activities of these two uridine nucleotides. HPLC
analysis of medium bathing the mucosal surface of HNE cells
revealed the presence of an ecto-nucleotidase(s) that hydro-
lyzed [3H]UTP and [3H]UDP with t1⁄2 values (at 1 mM nucle-
otide) of 14 and 27 min, respectively. An ecto-nucleoside
diphosphokinase activity also was observed, which promoted
conversion of [3H]UDP into [3H]UTP in the presence of ATP.
The effects of UDP on [3H]inositol phosphate accumulation,
intracellular calcium levels ([Ca21]i), and Cl2 secretory rates
(ICl2) were quantitated in HNE cells in the presence of
hexokinase and glucose to ensure that no UTP (or ATP)
contaminated UDP solutions during the assays. Although
UDP does not activate the human P2Y2 receptor, mucosal
addition of UDP promoted [3H]inositol phosphate accumu-
lation with an EC50 of 190 nM. Mucosal addition of UTP
stimulated [3H]inositol phosphate accumulation with an EC50
of 280 nM. The maximal effects of mucosal UDP on [3H]-
inositol phosphate, [Ca21]i, and ICl2 responses were approx-
imately one-half of those observed with mucosal UTP. Serosal
application of UTP promoted a 50% greater [3H]inositol
phosphate and calcium response than did mucosal application
of UTP. In contrast, UDP had no effect when added to the
serosal medium. Repetitive mucosal applications of UDP to
HNE cells resulted in a progressive loss, i.e., desensitization,
of the [Ca21]i and ICl2 response to UDP, whereas the corre-
sponding responses to UTP remained unchanged. Our results
provide evidence for the existence of a UDP receptor on HNE
cells that is pharmacologically distinct from the P2Y2 recep-
tor. The relative stability of UDP on the airway surface and the
apparent predominant mucosal expression of this putative
UDP receptor make it a potential target for cystic fibrosis
treatment.
Extracellular ATP regulates physiological responses in many
tissues and cell types through a multi-gene family of P2
receptors (1–4). The existence of receptors that selectively
recognize pyrimidines was proposed more than a decade ago
(see ref. 5). However, support for the idea of specific pyrim-
idinergic receptors was lessened by the fact that the stimulatory
activity of UTP in many tissues was mirrored by similar effects
of ATP and by the eventual cloning of the P2Y2 (P2U-
purinergic) receptor, which is equipotently activated by the
purine ATP and the pyrimidine UTP. Nonetheless, a novel
receptor was identified on C6–2B rat glioma cells that is
activated by UDP but not by adenine nucleotides (6), and two
recently cloned G protein-coupled P2Y receptors, the P2Y4
and P2Y6 receptors, show high selectivity for uridine nucleo-
tides and are activated only weakly or not at all by adenine
nucleotides (7–10). The P2Y6 receptor, which is potently and
selectively activated by UDP, subsequently was shown to be
expressed endogeneously by C6–2B cells (11). Although
mRNA for the P2Y6 receptor was detected in several tissues,
including aortic smooth muscle cells, spleen, kidney, stomach,
lung, intestine, and heart (7, 8), functional evidence for uridine
nucleotide selective receptors in native tissues is limited.
Uridine nucleotide analogues that might discriminate be-
tween uridine nucleotide-selective receptors and the widely
expressed P2Y2 receptor have not been available. The insta-
bility of most nucleotides in aqueous solution and metabolic
interconversion of UTP and UDP during incubation with cells
contribute additional problems. For example, we (12) and
others (13) initially reported that UDP was a full agonist at the
P2Y2 receptor, and Communi et al. (8) reported that UDP was
a full and potent agonist at the P2Y4 receptor. However, we
recently have demonstrated that UTP-free UDP is essentially
inactive at both receptor types (11). Conversely, while Chang
et al. (7) originally reported that UTP was the most potent
agonist at the P2Y6 receptor, we have observed that UDP is at
least 100-fold more potent than UTP (11), and the initially
reported effects of UTP were likely due to contamination with
UDP or formation of UDP during incubation with cells.
In this study we have adopted conditions that allow for
examination of the biological effects of UDP on primary
cultures of polarized human nasal epithelial cells. We report
that UDP potently stimulates formation of inositol phosphates,
calcium mobilization, and chloride secretion in airway epithe-
lial cells, and that the effects of UDP are not explained by
activation of a P2Y2 receptor. The response to UDP is
restricted to the mucosal surface of these human airway cells.
MATERIALS AND METHODS
Cell Cultures. Human nasal epithelial cells were harvested
from turbinates (protease 14) (Sigma) for 24–48 h at 48C, as
previously described (14). Cytosolic Ca21 and inositol phos-
phate measurements were made on nasal cell monolayers
plated on porous Transwell Col filters (pore diameter 0.45 mm;
Costar) and maintained in Ham’s F-12 medium supplemented
with 10 ngyml epidermal growth factor, 3.75 ngyml endothelial
cell growth factor, 500 ngyml hydrocortisone, 5 ngyml insulin,
and 1 mM CaCl2 (F121 4X medium). Assays were carried out
7–10 days after seeding, a time coincident with the develop-
ment of the maximal transepithelial potential difference (16).
Measurement of Inositol Phosphates. Confluent cells were
labeled for 18 h in inositol-free DMEM containing 4.5 gyliter
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glucose and 5 mCiyml [3H]myo-inositol (1 Ci 5 37 GBq). The
cells were preincubated with 10 mM LiCl and challenged with
agonists for an additional 10 min. No changes of medium were
made subsequent to the addition of [3H]myo-inositol to avoid
release of endogenous ATP from stressed cells (12). Incuba-
tions were terminated by the addition of 5% ice-cold trichlo-
roacetic acid and the resultant [3H]inositol phosphates were
separated on Dowex AG1-X8 columns as described (15).
Combined Bioelectric and Cytosolic Ca21 Measurements.
Nasal cells grown on Transwell Col filters affixed to O-rings
were maintained in F12 1 4X medium and studied 7–10 days
after cell plating as described above. For Ca21i measurements,
cells were loaded with Fura-2 and mounted in a miniature
Ussing chamber over an objective of a microscope (Zeiss)
coupled to a microfluorimeter, and cytosolic Ca21i levels were
quantitated as described (15). The fluorescence intensity ratio
(excitation 340y380; emission $450 nm) was collected from a
field of 30–40 nasal cells on monolayers and converted to Ca21
concentration as described (17). For simultaneous measure-
ments of Cl2 secretion, the transepithelial potential difference
was measured by a Voltage-ClampyPulse Generator (Model
VCC600, Physiologic Instruments, San Diego) and recorded
on a two-channel recorder (Linsesis model L200S). To calcu-
late changes in Cl2 secretory current (DICl2), a defined 1-s
current pulse was delivered across the monolayer every 10 s.
The nasal tissue was converted from its native Na1 absorptive
state to a Cl2 secretory state by exposing monolayers to a
luminal medium containing 0 Na1ylow Cl2 and to a basolat-
eral medium of Krebs bicarbonate Ringer solution.
Hydrolysis of [3H]UTP and [3H]UDP. Nasal monolayers
were grown to confluence on 6.5-mm transwells (Costar) as
indicated above. The cells were washed twice and preincubated
with 300 ml of Hepes-buffered (pH 7.4) DMEM medium for
at least 1 h prior to the addition of the [3H] nucleotides to
ensure that any endogeneously released ATP was degraded.
Incubations were initiated by the addition of 1 mM [3H]UTP
or [3H]UDP (0.5 mCi each) to either cell surface. Incubations
were terminated at the indicated times by transferring the
medium to a tube containing 30 ml of 50 mM EDTA and
boiling for 2 min.
Nucleoside Diphosphokinase Assay. To assay for the pres-
ence of ecto-nucleoside diphosphokinase activity, cells were
incubated with [3H]UDP as detailed above and ATP (100 mM)
was included in the incubation medium. The ATP-dependent
conversion of [3H]UDP to [3H]UTP was quantitated as de-
scribed (18).
HPLC Analysis. Nucleotides were separated by HPLC (Shi-
madzu) via a strong anion exchange column (Rainin Instru-
ments) (18) using a two-solvent system consisting of buffer A
(45 mM ammonium formate, pH 4.6) and buffer B (250 mM
sodium phosphate, pH 2.7). A linear gradient was developed
from 100% buffer A to 100% B during the first 25 min. The
column then was eluted with 100% buffer B for the following
15 min and with 100% buffer A for an additional 15 min from
45 to 60 min. Absorbance at 260 nm was monitored with an
LSA UV detector (Shimadzu), and radioactivity was moni-
tored online with a Flo-One detector (Packard). [3H]Nucle-
otides and [3H]nucleosides were quantitated as described (18).
Enzymatic Conversion of UTP to UDP. Accurate delinea-
tion of the pharmacological selectivities of nucleotide recep-
tors is hampered by impurities frequently present in nucleotide
solutions and by potential ecto-enzyme-catalyzed interconver-
sion between triphospho- and diphosphonucleotides. Com-
mercial preparations of UDP contain up to 2% UTP. There-
fore, we have taken advantage of the enzymatic activity of
hexokinase, which in the presence of glucose transfers the
g-phosphate of ATP to glucose producing ADP and glucose
6-phosphate as products (19). Although ATP is the preferen-
tial substrate for hexokinase, other nucleoside triphosphates
also serve as g-phosphate donors although at slower rates of
reaction (19). Hexokinase (1 unityml) hydrolyzed UTP at a 60-
to 80-fold slower rate than the hydrolysis of ATP (Fig. 1A).
However, incubation of 1 mM UTP with 10 unitsyml hexoki-
nase resulted in quantitative conversion of UTP to UDP (Fig.
1B). To ensure that no UTP contaminated UDP, we routinely
preincubated stock solutions of UDP (1 mM) with 10 unitsyml
hexokinase and 25 mM glucose for 1 h prior to assays.
Synthesis of [3H]UDP. [3H]UDP was prepared by incubat-
ing [3H]UTP with hexokinase and glucose followed by boiling
for 2 min, as indicated above.
Materials. UTP and ATP were obtained from Pharmacia,
and UDP and hexokinase were from Boehringer Mannheim.
[3H]myo-inositol (20 Ciymmol) was from ARC (St. Louis) and
[3H]UTP and [3H]ATP (97% and 99% pure, respectively)
(17–20 Ciymmol) were from Amersham.
FIG. 1. Hexokinase (HK) catalyzes the conversion of [3H]UTP to
[3H]UDP. (A) Time course for ATP and UTP hydrolysis in the
presence of 1 unityml HK. Incubations were carried out at 378C in 1
ml Hepes-buffered DMEM (pH 7.4) containing 25 mM glucose and
1 mM (0.5 mCi) of either [3H]ATP or [3H]UTP. At the times indicated,
5 mM EDTA was added to the samples followed by boiling. (B) Time
course for the conversion of [3H]UTP to [3H]UDP in the presence of
10 unitsyml HK. Incubations were as indicated above except for the
HK concentration. The [3H]species were resolved by HPLC as de-
tailed. The results are expressed as the percent conversion of
[3H]nucleotide triphosphate to [3H]nucleotide diphosphate. Data
indicate the mean value of one experiment representative of two
independent experiments performed with duplicate samples that
differed by less than 20%.
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RESULTS
The metabolism of [3H]UDP and [3H]UTP by human airway
epithelial cell surfaces was examined. Incubation of 1 mM
[3H]UTP for 20 min on the mucosal surface resulted in 73 6
16% hydrolysis indicating the presence of ecto-nucleotidases
andyor phosphatases. [3H]UDP accumulated as the major
breakdown product of [3H]UTP (Fig. 2A). Mucosal [3H]UDP
(1 mM) also was hydrolyzed, although to a lesser extent than
[3H]UTP (Fig. 2B). Time course experiments indicated that
the half-life (t1⁄2) values for mucosal [3H]UTP and [3H]UDP
were 14 6 2 min and 27 6 3 min, respectively (not shown).
Hydrolysis of both [3H]UTP and [3H]UDP was determined on
both cell surfaces and the data are summarized in Table 1.
Nucleoside diphosphokinase catalyzes the transfer of the
g-phosphate from nucleoside triphosphates to nucleoside
diphosphates. We previously have observed the presence of a
nucleoside diphosphokinase activity on the surface of 1321N1
human astrocytoma cells, which converts UDP (and ADP) to
UTP (or ATP) and confounds analyses of the pharmacological
effects of diphosphonucleotides. To examine the potential
presence of ecto-nucleoside diphosphokinase activity in airway
epithelial cells, [3H]UDP was added to the mucosal surface in
combination with ATP (Fig. 2C). [3H]UTP was rapidly formed
under these conditions, and similar results were obtained with
either 0.1 mM or 100 mM [3H]UDP. Comparable results also
were obtained in experiments examining nucleoside diphos-
phokinase activity on the serosal side (data not shown). Since
potential ATP release from epithelial cells during tissue
manipulations and consequential phosphorylation of UDP to
UTP by nucleoside diphosphokinase may complicate study of
the actions of UDP, hexokinase (2 unitsyml) and glucose were
included in all subsequent assays examining the effects of UDP
(see Materials and Methods and Fig. 1). No accumulation of
[3H]UTP occurred under these incubation conditions (not
shown).
Primary cultures of polarized human airway epithelial cells
express P2Y2 receptors on both cell surfaces (20). We have
reported that functional expression of the P2Y2 receptor in
polarized human nasal epithelial cells is asymmetric and that
the receptor apparently couples more efficaciously to its
effector phospholipase C on the serosal (basolateral) surface
than on the mucosal (apical) surface (15). Consistent with this
previous study, UTP (100 mM) promoted larger [3H]inositol
phosphate and calcium responses when applied to the baso-
lateral bath of polarized primary human nasal epithelial cells
than when applied to the mucosal bath (Fig. 3). The Cl2
secretory responses (DICl2) following addition of 100 mMUTP
to either the mucosal or the serosal bath were 746 11 mA/cm2
and 34 6 3 mAycm2, respectively. Application of UDP to the
serosal bath had negligible effect on inositol phosphate accu-
mulation. In contrast, mucosal UDP (100 mM) promoted
marked accumulation of [3H]inositol phosphates and calcium
mobilization, and the maximal effects of UDP were approxi-
mately one-half the magnitude of the responses observed with
mucosal UTP (Figs. 3 and 4). Similarly, mucosal but not
serosal UDP stimulated Cl2 secretion (DICl2 5 216 6 3
mAzcm2 for 3 mM mucosal UDP; DICl2 5 0 6 0 mAzcm2 for 3
mM serosal UDP) and the magnitude of this response was
approximately one-half of the mucosal UTP response (Fig. 4).
The effects of mucosal application of UDP cannot be ex-
plained by activation of P2Y2 receptors, since UTP-free UDP
is essentially inactive at the P2Y2 receptor (11) and because
UDP caused little or no effect when applied to the P2Y2
receptor-expressing serosal side of the cell monolayers (Figs.
3 and 4). The larger mucosal versus serosal effect of UDP
contrasts with the predominantly basolateral effects of UTP
(Fig. 3) and ATP (15). Thus, the action of UDP in polarized
airway epithelial cells does not coincide with that observed
with P2Y2 receptor agonists (Figs. 3 and 4, and ref. 11)
Although mucosal UDP was less efficacious than mucosal
UTP in stimulating inositol phosphate formation in human
nasal epithelium, UDP (EC50 5 1906 27 nM) and UTP (EC50
5 280 6 35 nM) exhibited similar potencies (Fig. 5). Cross-
desensitization experiments were carried out to further ad-
dress the hypothesis that UDP promotes signaling responses in
airway cells through a receptor distinct from the P2Y2 receptor
(Fig. 4). Addition of 3 mM of UDP to the mucosal bath
promoted mobilization of intracellular calcium with a DCa21
of 666 12 nM, and changes in Cl2 secretory responses (DICl2)
of 216.3 6 3 mAycm2 (n 5 8). Subsequent addition of 3 mM
UDP followed by 10 mM UDP did not result in elevation of
intracellular Ca21 (DCa21 5 0) or in Cl2 secretion (DICl2 5 0),
FIG. 2. Metabolism of [3H]UTP and [3H]UDP by human nasal
epithelial cells. Confluent polarized cells were incubated for 20 min at
378C in the presence of 1 mM (0.2 mCi) of [3H]UTP (A), [3H]UDP (B),
or [3H]UDP combined with 100 mM ATP (C). All additions were to
the mucosal bath (final volume, 300 ml). Incubations were terminated
by transferring the mucosal medium to an Eppendorf tube containing
30 ml of 50 mMEDTA followed by boiling. [3H]Species were separated
by HPLC as described. The traces are representative of at least three
independent experiments performed with duplicates.
Table 1. Hydrolysis of [3H]UTP and [3H]UDP by the mucosal and




[3H]UTP 147 6 22 98 6 11
[3H]UDP 87 6 9 70 6 9
Primary cultures of human nasal epithelium cells were grown to
confluence on 6.5-mm transwells as a polarized epithelium. The cells
were washed twice with prewarmed DMEM–Hepes medium (pH 7.4),
and were pre-incubated for 1 h at 378C with 0.5 ml of medium added
on each side. Incubations were initiated by the addition 50 ml of 10 mM
(0.5 mCi) [3H]UTP or [3H]UDP on the indicated cell surface. Medium
samples were collected after a 20-min incubation period and analyzed
by HPLC as described. The values represent the mean (6 range from
the mean) from two experiments performed with duplicate samples.
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which suggests the occurrence of UDP-induced desensitization
(Fig. 4). In contrast, responses to UTP [DCa21 5 3746 24 nM
(n 5 19); DICl2 5 274 6 11 mA/cm2 (n 5 12)] were retained
in cells that were pretreated with UDP [DCa21 5 3106 35 nM
(n5 8);DICl2 5 2646 10mAycm2 (n5 8)] (Fig. 4). Responses
to ATP also were retained following multiple additions of
UDP (not shown).
DISCUSSION
Existence of a G protein-coupled receptor that selectively
recognizes UDP was originally established in studies of a
receptor natively expressed by C6–2B rat glioma cells (6). The
P2Y6 receptor recently was cloned by Chang et al. (7), and this
receptor subsequently was shown to be selectively activated by
UDP and to be the UDP receptor natively expressed in C6–2B
cells (11). The broad distribution of mRNA encoding this
UDP-selective receptor suggests that it may be of widespread
physiological significance (7, 8). Failure to identify this recep-
tor in previous studies of mammalian tissues likely has been a
consequence of lack of availability of potent selective agonists
for uridine nucleotide receptors and the low chemical and
metabolic stability of the available nucleotides. We originally
reported that UDP stimulated inositol phosphate accumula-
tion in human airway epithelial cells by low potency activation
of the P2Y2 (P2U-purinergic) receptor (12, 21). However, we
recently demonstrated that UDP is in fact not an agonist at the
P2Y2 receptor (11), and that the previously observed effect of
UDP at P2Y2 receptors can be explained by the presence of
small amounts of contaminating UTP in UDP solutions
andyor by conversion of UDP to UTP by cell surface nucle-
oside diphosphokinase.
This study illustrates that although UDP is not a P2Y2
receptor agonist, it nonetheless is a potent agonist at the
human airway epithelial cell surface. The effects of UDP could
not be attributed to contamination with UTP. Solutions of
UDP were preincubated with hexokinase and glucose to
eliminate any traces of UTP, and hexokinase and glucose were
included in studies of epithelial cells to prevent metabolic
conversion of UDP to UTP by cell surface nucleoside diphos-
phokinases and endogenously released ATP. HPLC analysis of
FIG. 4. Representative tracings of UDP- and UTP-promoted
changes in intracellular Ca21 concentration and Cl2 diffusion poten-
tials in human nasal epithelial cells. Primary cultures of human nasal
epithelial cells were mounted on modified Ussing chambers as de-
scribed. Changes in Ca21 concentration (top tracings) or in Cl2
secretion (bottom tracings) were simultaneously recorded after the
addition to the basolateral medium of 100 mM UDP followed by 100
mM UTP (serosal), or after two consecutive additions of 3 mM UDP
and then 10 mMUDP to the apical medium followed by the ipsilateral
addition of 10 mMUTP (mucosal). Data are representative of at least
eight independent experiments.
FIG. 3. Sidedness of UTP and UDP effects on [3H]inositol phos-
phate formation and intracellular calcium mobilization in polarized
human nasal epithelial cells. Confluent cells were loaded with
[3H]myo-inositol and preincubated with LiCl (A) or with Fura-2 (B)
as described. The cells were challenged with 100 mM of the indicated
nucleotide, added to either the serosal or the mucosal medium. The
results represent the mean (6SEM) from three experiments per-
formed with triplicates (A) or from 14 individual experiments (B).
FIG. 5. Concentration-response relationship for mucosal UDP-
and UTP-stimulated [3H]inositol phosphate formation in human nasal
epithelial cells. Confluent cells were labeled with [3H]myo-inositol,
preincubated with LiCl as described, and subsequently challenged for
10 min with the indicated concentration of UDP or UTP added to the
mucosal medium. Data represent the mean value (6SEM) from three
independent experiments performed with triplicate samples.
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UDP solutions before and after incubation with cells indicated
the absence of UTP (data not shown). The almost equal
potency of UDP and UTP on the airway cells notably contrasts
with the low apparent activity of UDP at P2Y2 receptors (11).
The asymmetry of the effect of UDP on polarized epithelium,
with a preferred mucosal versus serosal activity, also contrasts
with the predominant serosal effect of UTP (and ATP) in
airway cells. Because UDP does not activate the epithelial cell
P2Y2 receptor, the simplest explanation for the stimulatory
effect of this diphosphate is the existence of a novel airway
receptor that selectively recognizes UDP. The likely candidate
for the effect of UDP in the airways is the P2Y6 receptor,*
although the contribution of this receptor remains to be proven
unambiguously.
The potential implications of these results are 2-fold. First,
we have demonstrated that, in the presence of the apparently
more abundant P2Y2 receptor, assay conditions can be estab-
lished that allow resolution of a receptor that is selectively
activated by UDP. Specifically, hexokinase and glucose can be
used to study effects of UDP in tissues where UDP-selective
effects are otherwise masked by a prominent P2Y2 receptor.
Second, the asymmetry of the effects of UDP and UTP in
polarized epithelial cells suggests different regulatory func-
tions for the receptors recognizing these two nucleotides.
Activators of receptors on the serosal surface may be released
at distant sites and access receptors via the bloodstream,
whereas UDP, which acts exclusively on the mucosal side of
airway epithelial cells, may be generated locally.WhetherUDP
is released per se from epithelial andyor other cells remains to
be shown. However, mucosal UTP is hydrolyzed at a 2- to
3-fold faster rate than mucosal UDP, and consequently, UDP
likely accumulates on the apical surface after the breakdown
of UTP. Thus, released UTP could be an important source of
extracellular UDP, which in turn potentially serves as a
physiologically important signaling molecule in human airway
tissue.
Confirmation of the presence of P2Y2 receptors on the
apical surface of human airway epithelial cells raised the
possibility that aerosolized nucleotides might be used thera-
peutically to induce Cl2 secretion in individuals with cystic
fibrosis or other airway diseases (22). Because the expression
of receptors and patterns of ion transport are similar in nasal
and bronchial epithelia (23, 24), it is likely that our data in
nasal epithelia are relevant to diseased lower airways in cystic
fibrosis. UTP, the most potent agonist for P2Y2 receptors, is
currently undergoing clinical assessment as an agent to modify
airway disease in cystic fibrosis patients (25). The results of this
study indicate that a receptor that selectively recognizes UDP
as a potent agonist also exists in airway tissue. The functional
importance of this receptor and its molecular identity need to
be established rigorously, and analogues of UDP that are
potent, selective, and stable agonists of this receptor need to
be identified. Our initial association of this receptor with
increases in Cl2 secretion suggests that UDP or receptor-
selective drugs derived from this natural molecule could be of
potential therapeutic value for the treatment of airway dis-
eases.
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